TY - JOUR
T1 - Recombinant activated factor VII for non-hemophiliac bleeding patients
AU - Uhlmann, Erik J.
AU - Eby, Charles S.
PY - 2004/5/1
Y1 - 2004/5/1
N2 - The purpose of this review: The purpose of this review is to summarize the safety and efficacy of recombinant activated factor VII in diverse clinical settings based on recent published anecdotal experiences and early results from prospective trials. Recent findings: Recombinant activated factor VII is increasingly being used for off-label treatment and prophylaxis of bleeding in non-hemophiliac patients. Case reports would suggest that recombinant activated factor VII is an efficacious and safe "universal hemostatic agent". To date, results of several randomized control trials investigating recombinant activated factor VII in non-hemophiliacs have been published as abstracts, supporting recombinant activated factor VII safety, but not its efficacy. Summary: Until the results of additional prospective trials are available, clinicians, who manage patients with challenging hemostatic complications, and transfusion medicine specialists should collaborate to develop local policies for off-label utilization of recombinant activated factor VII.
AB - The purpose of this review: The purpose of this review is to summarize the safety and efficacy of recombinant activated factor VII in diverse clinical settings based on recent published anecdotal experiences and early results from prospective trials. Recent findings: Recombinant activated factor VII is increasingly being used for off-label treatment and prophylaxis of bleeding in non-hemophiliac patients. Case reports would suggest that recombinant activated factor VII is an efficacious and safe "universal hemostatic agent". To date, results of several randomized control trials investigating recombinant activated factor VII in non-hemophiliacs have been published as abstracts, supporting recombinant activated factor VII safety, but not its efficacy. Summary: Until the results of additional prospective trials are available, clinicians, who manage patients with challenging hemostatic complications, and transfusion medicine specialists should collaborate to develop local policies for off-label utilization of recombinant activated factor VII.
KW - Coagulopathy
KW - Life-threatening hemorrhage
KW - Non-hemophilia bleeding
KW - Recombinant activated factor VII
UR - http://www.scopus.com/inward/record.url?scp=3242709784&partnerID=8YFLogxK
U2 - 10.1097/01.moh.0000135405.29702.3c
DO - 10.1097/01.moh.0000135405.29702.3c
M3 - Review article
C2 - 15257021
AN - SCOPUS:3242709784
SN - 1065-6251
VL - 11
SP - 198
EP - 204
JO - Current opinion in hematology
JF - Current opinion in hematology
IS - 3
ER -